James F Marion, MD
- PROFESSOR | Medicine, Gastroenterology
MD, Columbia Univ. Col. of Phy. & Surg.
Residency, Internal Medicine, Columbia-Presbyterian Medical Ctr.
Residency, Internal Medicine, Columbia-Presbyterian Medical Center
Fellowship, Gastroenterology, Mount Sinai Hospital
- A Double-Blind Randomized Multicenter Study of Higher Versus Standard Adalimumab Dosing Regimens for Induction and Maintenance Therapy in Subjects with Moderately to Severely Active Ulcerative Colitis
This is a Phase 3 double-blind randomized multicenter study of higher versus standard adalimumab dosing regimens for induction and maintenance therapy in subjects with moderately to severely active UC. This study will include a 3-Week Screening Period; an 8-Week Double-Blind I...
- A Multicentre, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of Oral CP-690,550 as a maintenance therapy in subjects with moderate to severe Ulcerative Colitis
The purpose of this study is to find out if a new investigational drug, called tofacitinib (also known as tofacitinib citrate or CP-690,550) can help people with Ulcerative Colitis (UC). A new investigational drug is one that is currently not approved for sale in this co...
- A Combined Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Induction and Maintenance Study Evaluating the Safety and Efficacy of GS-5745 in Subjects with Moderately to Severely Active Ulcerative Colitis
The purpose of this study is to see how safe and effective an experimental drug named GS-5745 is in treating people with moderate to severe Ulcerative Colitis (an inflammatory disease of the intestine). Subjects may qualify to take part in this research study because they have...
- A Multicenter Randomized Double-Blind Study to Evaluate the Efficacy and Safety of Two Adalimumab Induction Regiments in Subjects with Moderately Severely Active Crohn's Disease and Evidence of Mucosal Ulceration
This is a randomized double-blind multicenter study of two adalimumab induction regimens in subjects with moderately to severely active Crohn's Disease (CD) with evidence of mucosal ulceration confirmed by central reading. No placebo arm is planned since there is well-document...